Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management.

MLA

Khan, Khurum H., et al. “Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/MTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management.” The Oncologist, vol. 21, no. 7, July 2016, pp. 855–60. EBSCOhost, https://doi.org/10.1634/theoncologist.2015-0248.

APA

Khan, K. H., Wong, M., Rihawi, K., Bodla, S., Morganstein, D., Banerji, U., & Molife, L. R. (2016). Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management. The Oncologist, 21(7), 855–860. https://doi.org/10.1634/theoncologist.2015-0248

Chicago

Khan, Khurum H, Mabel Wong, Karim Rihawi, Shankar Bodla, Daniel Morganstein, Udai Banerji, and Lulama R Molife. 2016. “Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/MTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management.” The Oncologist 21 (7): 855–60. doi:10.1634/theoncologist.2015-0248.